AstraZeneca PLC (AZN)vsHaemonetics Corporation (HAE)
AZN
AstraZeneca PLC
$155.62
+3.78%
HEALTHCARE · Cap: $263.09B
HAE
Haemonetics Corporation
$85.38
-1.62%
HEALTHCARE · Cap: $3.89B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 4500% more annual revenue ($61.37B vs $1.33B). AZN leads profitability with a 17.0% profit margin vs 7.3%. HAE appears more attractively valued with a PEG of 1.35. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
HAE
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$155.62
$41.31 discount
Margin of Safety
+33.5%
Fair Value
$86.50
Current Price
$85.38
$1.12 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Earnings expanding 28.4% YoY
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
4.8% revenue growth
Distress zone — elevated risk
7.3% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : HAE
The strongest argument for HAE centers on EPS Growth. PEG of 1.35 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : HAE
The primary concerns for HAE are Revenue Growth, Altman Z-Score, Profit Margin. A P/E of 41.3x leaves little room for execution misses. Debt-to-equity of 1.54 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while HAE is a value play — different risk/reward profiles.
HAE carries more volatility with a beta of 0.52 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 56/100), backed by strong 17.0% margins. HAE offers better value entry with a 33.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Haemonetics Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?